---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-25-000006"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2025-01-21T23:59:59+00:00"
generated_at: "2026-05-27T22:08:38.083406+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolus posts record FY2024 revenue $266.3M (+32%); guides 2025 $345-355M; FDA for HA gels within 90 days

## Summary
- Preliminary Q4 2024 net revenue $79.0M (+30% YoY); FY2024 net revenue $266.3M (+32% YoY) at top of guidance ($260-266M).
- Expects FDA approval within 90 days for Evolysse Form and Smooth HA gels; US launch planned Q2 2025, a quarter ahead of prior timeline.
- 2025 revenue guidance $345-355M (30-33% growth); non-GAAP operating expenses $230-240M; positive non-GAAP operating income expected for full-year 2025.
- Cash and equivalents $87M as of Dec 31, 2024, up from $85M on Sep 30; >15,300 accounts purchasing Jeuveau since launch.
- Evolus Rewards enrollment grew over 40% to ~1.1M; Q4 redemptions record ~220,000, with ~60% from repeat treatments.

## SEC filing metadata
- accession: 0001570562-25-000006
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2025-01-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056225000006/0001570562-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056225000006/eols-20250121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-25-000006
- JSON: https://secwatch.observer/filing/0001570562-25-000006.json
- Plain text: https://secwatch.observer/filing/0001570562-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.